"Dyskinesia and impulsivity in Parkinson disease, cognitive defects in attention deficit-hyperactivity disorder (ADHD), and now attention and memory in mild cognitive impairment (MCI): the list of reported neurological benefits just keeps growing in animal and human studies of nicotine," he wrote. "The latest study, published in the Jan. 10 Neurology, involved 67 subjects with amnestic MCI randomized for six months to either placebo or 15 mg per day of transdermal nicotine. The results found 'significant nicotine-associated improvements in attention, memory, and psychomotor speed,' with excellent safety and tolerability. 'The idea that nicotine would have positive therapeutic effects on brain function is still a novel idea to a lot of people,' said the senior author of the paper, Paul Newhouse, MD, professor of psychiatry, pharmacology and medicine, and director of the Center for Cognitive Medicine at Vanderbilt University School of Medicine in Nashville. 'Nicotine obviously carries a lot of baggage,' he told Neurology Today, 'but this paper is based on work we started doing in the late 1980s on the beneficial effects of nicotine in Alzheimer disease. There are now clinical trials of nicotine in Parkinson disease.'"